Leucine Zipper, Putative Tumor Suppressor 1 (LZTS1) Peptide
LZTS1
Reactivity: Human
Host: Synthetic
BP, WB
-
- Target See all LZTS1 products
- LZTS1 (Leucine Zipper, Putative Tumor Suppressor 1 (LZTS1))
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-LZTS1 antibody (Catalog #: ARP39473_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- LZTS1 (Leucine Zipper, Putative Tumor Suppressor 1 (LZTS1))
- Synonyms
- F37 Peptide, FEZ1 Peptide, Psdzip70 Peptide, LZTS1 Peptide, f37 Peptide, fez1 Peptide, leucine zipper tumor suppressor 1 Peptide, leucine zipper, putative tumor suppressor 1 Peptide, LZTS1 Peptide, Lzts1 Peptide, lzts1 Peptide
- Background
-
LZTS1 involved in the regulation of cell growth. LZTS1 may stabilize the active CDC2-cyclin B1 complex and thereby contribute to the regulation of the cell cycle and the prevention of uncontrolled cell proliferation. LZTS1 may act as tumor suppressor and defects in LZTS1 are found in many types of tumors.
Alias Symbols: F37, FEZ1
Protein Interaction Partner: CDC25C,CDK1,EEF1G,CDK1,EEF1G
Protein Size: 596 - Molecular Weight
- 67 kDa
- Gene ID
- 11178
- NCBI Accession
- NM_021020, NP_066300
- UniProt
- Q9Y250
-
You are here:
